

## **PIPELINE VCC-002**

## VCC-002 IS DEVELOPED TO TREAT DEVELOPING METASTASIS IN RCC. LOCALIZED RCC IS PROGRESSING IN UP TO 50% OF PATIENTS.

General: Principles developed for the autologous tumour vaccine VCC-001 can also be applied or extended to other tumours with unmet medical needs which are amenable to surgery or to other stages of tumours (even including metastases) for which enough tumour material can be obtained by surgery.



Child

29 k Stage III patients

## **36.6** k

Stage IV patients VCC-002 POTENTIAL

**170 k** RCC (Renal Cell Cancer) Cases p.a.

/230511